Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

89bio's NASH Candidate Shows Improvement In Disease Severity, Cardiovascular Health

89bio Inc (NASDAQ:ETNBannounced topline results from a cohort of 20 patients (Cohort 7) in the Phase 1b/2a proof-of-concept study evaluating pegozafermin (formerly BIO89-100) for nonalcoholic steatohepatitis (NASH).

  • The results show that 63% of patients achieved a two-point or greater improvement in disease severity without worsening fibrosis (primary endpoint). 
  • 89bio also said 74% of patients achieved the two-point improvement alone.
  • NASH resolution without worsening of fibrosis was observed in 32% of patients, and 47% experienced NASH resolution or fibrosis improvement.
  • 89bio also reported that pegozafermin improved a series of cardio-metabolic measures such as glycemic control, lipids, and body weight.
  • No adverse events have been reported, and one patient has discontinued due to the treatment.
  • The Company is evaluating pegozafermin in ENLIVEN Phase 2b trial, including 200 patients with a follow-up biopsy performed after 24 weeks of treatment. 
  • The therapy is also being tested in patients with severe hypertriglyceridemia in ENTRIGUE Phase 2 trial. 
  • The trials are expected to read out in 1H of 2023 and 2H of 2022, respectively.
  • As per the new sub-analysis presented at The Liver Meeting 2021, pegozafermin treatment reduced spleen volume by an average of 11.8% in NASH patients.
  • Price Action: ETNB shares are up 2.81% at $9.87 during the premarket session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.